Simultaneous 24 h-infusion of high-dose 5-fluorouracil and sodium-folinate as alternative to capecitabine in advanced breast cancer

Anticancer Research

Volumn 34, Issue 12, 2014, Pages 7233-7238

  Terjung, Arne ^a   Kummer, Silke ^a   Friedrich, Michael ^a  

^a HELIOS KLINIKUM KREFELD   (Germany)

Author keywords

5 FU; Advanced stage breast cancer; Chemotherapy; Metastatic breast cancer; Sodium folinate

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DOCETAXEL; DOXORUBICIN; ERIBULIN; FLUOROURACIL; NAVELBINE; PACLITAXEL; SODIUM FOLINATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; FOLINIC ACID; VITAMIN B COMPLEX;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HYPERTRANSAMINASEMIA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BREAST; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE; VITAMIN B COMPLEX;

EID: 84918515185     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, Richman S, Legaspi A, Waldman S and Morrell L: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol: official journal of the American Society of Clinical Oncology 9: 625-630, 1991.
2. Barrios CH, Sampaio C, Vinholes J and Caponero R: What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer? Ann Oncol 20: 1157-1162, 2009.
3. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A and Osterwalder B: Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92: 1759-1768, 2001.
4. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999.
5. Cardoso F, Castiglione M and Group ObotEGW: Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv15-iv18, 2009.
6. Cardoso F, Di Leo A, Lohrisch C, Bernard C, Ferreira F and Piccart MJ: Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13: 197-207, 2002.
7. Chekerov R, Mahner S, Braicu I, Harterer P, Fuxius S and Sehouli J: Preference Study: Choice of oral or intravenous treosulfan and clinical outcome in elderly patients with recurrent ovarian cancer - final analysis. Int J Gyn Cancer 22: E289, 2012.
8. Cortes J, OShaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J and Twelves C: Eribulin monotherapy versus treatment of physicians choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377: 914-923, 2011.
9. Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere JF, Montestruc F, Mouri Z, and Namer M: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40: 536-542, 2004.
10. Gralow JR: Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Tr 89(Suppl 1): S9-S15, 2005.
11. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, and Hortobagyi GN: Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23: 6019-6026, 2005.
12. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, and Ravdin PM: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542-5551, 2005.
13. Largillier R, Ferrero J-M, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M and Chamorey E: Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 19: 2012-2019, 2008.
14. Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS and Yang CH: A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer. Anticancer res 27: 641-645, 2007.
15. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V and Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792-799, 2005.
16. Noordhuis P, Holwerda U, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM and Peters GJ: 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 15: 1025-1032, 2004.
17. OBrien MER, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L and Tendler C: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440-449, 2004.
18. OShaughnessy J: Extending Survival with Chemotherapy in Metastatic Breast Cancer. Oncologist 10: 20-29, 2005.
19. Porschen R, Arkenau H-T, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W and Schmoll H-J: Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223, 2007.
20. Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M and Luck HJ: Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14: 1227-1233, 2003.
21. Talbot DC, Moiseyenko V, Van Belle S, OReilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S and Osterwalder B: Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Brit J Cancer 86: 1367-1372, 2002.
22. Vogel C, ORourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, White R and McGuirt C: Vinorelbine as firstline chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 10: 397-402, 1999.
23. Wilke H, Klaassen U, Achterrath W, Losch M, Vanhoefer U, Hayungs J, Harstrick A, Stahl M, Eberhardt W, Becher R and Seeber S: Phase I/II study with a weekly 24-hour infusion of 5- fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 7: 55-58, 1996.
24. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y and Mjaaland I: Oral capecitabine in anthracycline- and taxanepretreated advanced/metastatic breast cancer. Acta Oncol 43: 186-189, 2004.